Open an account

Stoke Therapeutics

STOK · NASDAQ

$26.61+$1.79 (+7.21%)TodayMarket closed ·
Prev close $24.82

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 170 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Employees
170
Headquarters
Bedford, Massachusetts
Listed
Jun 19, 2019
Sector
Health Care
Industry
Biotechnology
Website
stoketherapeutics.com

STOK key statistics

Market cap
1.72B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
934.12K
Volume
2.46M
Open price
$24.95
High today
$27.22
Low today
$24.84
52 Week high
$40.22
52 Week low
$20.32

Stoke Therapeutics (STOK) at a glance

Stoke Therapeutics (STOK) last traded at $26.61, with a market cap of 1.72B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $24.84 and $27.22. The current price is 7.1% above the day's low and 2.2% below its high.

Volume so far is 2.46M shares, above the average of 934.12K shares a day.

Over the past year Stoke Therapeutics has ranged from $20.32 to $40.22, and now sits 32% of the way up that range.

Stoke Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.93 per share against an estimate of -$0.8112.

The average analyst price target is $47.94, 80.2% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 15 analystsAvg $47.94
Low
$35.35
Now
$26.61
High
$63.00

STOK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 133.7% on average.

  1. Q3 FY24: reported -$0.47 per share against an estimate of -$0.5434
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.5386
  3. Q1 FY25: reported $1.98 per share against an estimate of -$0.4317
  4. Q2 FY25: reported -$0.40 per share against an estimate of -$0.5222
  5. Q3 FY25: reported -$0.65 per share against an estimate of -$0.5797
  6. Q4 FY25: reported -$0.97 per share against an estimate of -$0.7279
  7. Q1 FY26: reported -$0.79 per share against an estimate of -$0.8435
  8. Q2 FY26: reported -$0.93 per share against an estimate of -$0.8112

STOK news

  • Press releaseBusiness Wire

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

  • Press releaseBusiness Wire

    Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

  • Press releaseBusiness Wire

    Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

  • Press releaseBusiness Wire

    Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

  • Press releaseBusiness Wire

    Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

  • Press releaseBusiness Wire

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

  • Press releaseGlobe Newswire

    Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

  • Press releaseBusiness Wire

    Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Similar companies

Companies in the same industry as Stoke Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.